GSK Argues Its Strategy Is Delivering As It Makes More Cuts, Including In R&D
GlaxoSmithKline CEO Andrew Witty declared on Feb. 4 that his strategy of building a global, diversified business was delivering. And to prove his point, he announced a return to full-year sales growth in 2009 after a negative 2008, and an upbeat forecast for 2010 as well
You may also be interested in...
Latest data suggest startup Axovant has a plausible path for its modestly effective RVT-101 toward approval, but the field is still inherently risky and the market is wary nevertheless.
GlaxoSmithKline takes aim at neurological symptoms of lysosomal storage diseases, increasing likely future competitive pressure on Sanofi's and Shire's rare disease products.
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.